Market Insights report
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.
What's included?
In the past years, the revenue in the Anti-Coagulants market has experienced strong growth, mainly driven by a strong increase in sales of direct oral anti-coagulants. While this trend is expected to continue for the next few years, several patents are going to expire. Since the start of the COVID-19 pandemic, limited access to healthcare facilities has triggered a shift away from warfarin, which requires monitoring, and injectables. Instead, more oral anti-coagulants have been used, compensating the negative impact of the pandemic and leading to notable growth in 2020.
Overview
Market numbers
We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)